Literature DB >> 34949766

Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.

Talia L Fuchs1,2,3, Fiona Maclean2,4,5, John Turchini1,2,4,5, A Cristina Vargas1,2,4,5, Selina Bhattarai6, Abbas Agaimy7, Arndt Hartmann7, Chia-Sui Kao8, Carla Ellis9, Michael Bonert10, Xavier Leroy11, Lakshmi P Kunju12, Lauren Schwartz13, Admire Matsika14,15, Sean R Williamson16, Priya Rao17, Mukul Divatia18, Rosa Guarch19, Ferran Algaba20, Marcelo L Balancin21, Ming Zhou22, Hemamali Samaratunga15,23, Isabela Werneck da Cunha24, Fadi Brimo25, Andrew Ryan26, David Clouston26, Manju Aron27, Marie O'Donnell28, Emily Chan29, Michelle S Hirsch30, Holger Moch31, Chun-Yin Pang32, Cheuk Wah33, Weihua Yin34, Joanna Perry-Keene23,35, Asli Yilmaz36, Angela Chou1,2,3, Adele Clarkson2,3, Gerhard van der Westhuizen37, Ella Morrison38, Jonathan Zwi39, Ondrej Hes40, Kiril Trpkov36, Anthony J Gill41,42,43.   

Abstract

Most succinate dehydrogenase (SDH)-deficient renal cell carcinomas (RCCs) demonstrate stereotypical morphology characterized by bland eosinophilic cells with frequent intracytoplasmic inclusions. However, variant morphologic features have been increasingly recognized. We therefore sought to investigate the incidence and characteristics of SDH-deficient RCC with variant morphologies. We studied a multi-institutional cohort of 62 new SDH-deficient RCCs from 59 patients. The median age at presentation was 39 years (range 19-80), with a slight male predominance (M:F = 1.6:1). A relevant family history was reported in 9 patients (15%). Multifocal or bilateral tumors were identified radiologically in 5 patients (8%). Typical morphology was present at least focally in 59 tumors (95%). Variant morphologies were seen in 13 (21%) and included high-grade nuclear features and various combinations of papillary, solid, and tubular architecture. Necrosis was present in 13 tumors, 7 of which showed variant morphology. All 62 tumors demonstrated loss of SDHB expression by immunohistochemistry. None showed loss of SDHA expression. Germline SDH mutations were reported in all 18 patients for whom the results of testing were known. Among patients for whom follow-up data was available, metastatic disease was reported in 9 cases, 8 of whom had necrosis and/or variant morphology in their primary tumor. Three patients died of disease. In conclusion, variant morphologies and high-grade nuclear features occur in a subset of SDH-deficient RCCs and are associated with more aggressive behavior. We therefore recommend grading all SDH-deficient RCCs and emphasize the need for a low threshold for performing SDHB immunohistochemistry in any difficult to classify renal tumor, particularly if occurring at a younger age.
© 2021. Crown.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34949766     DOI: 10.1038/s41379-021-00998-1

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  31 in total

1.  Renal tumors associated with germline SDHB mutation show distinctive morphology.

Authors:  Anthony J Gill; Nicholas S Pachter; Angela Chou; Barbara Young; Adele Clarkson; Katherine M Tucker; Ingrid M Winship; Peter Earls; Diana E Benn; Bruce G Robinson; Stewart Fleming; Roderick J Clifton-Bligh
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

2.  Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4.

Authors:  Anthony J Gill; Nicholas S Pachter; Adele Clarkson; Katherine M Tucker; Ingrid M Winship; Diana E Benn; Bruce G Robinson; Roderick J Clifton-Bligh
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

3.  Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.

Authors:  Sean R Williamson; Anthony J Gill; Pedram Argani; Ying-Bei Chen; Lars Egevad; Glen Kristiansen; David J Grignon; Ondrej Hes
Journal:  Am J Surg Pathol       Date:  2020-07       Impact factor: 6.394

4.  Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas.

Authors:  John Turchini; Anthony J Gill
Journal:  Am J Surg Pathol       Date:  2020-03       Impact factor: 6.394

Review 5.  Succinate dehydrogenase (SDH)-deficient neoplasia.

Authors:  Anthony J Gill
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

6.  Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.

Authors:  Anthony J Gill; Diana E Benn; Angela Chou; Adele Clarkson; Anita Muljono; Goswin Y Meyer-Rochow; Anne Louise Richardson; Stan B Sidhu; Bruce G Robinson; Roderick J Clifton-Bligh
Journal:  Hum Pathol       Date:  2010-03-17       Impact factor: 3.466

Review 7.  Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia.

Authors:  Anthony J Gill
Journal:  Pathology       Date:  2012-06       Impact factor: 5.306

8.  Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types.

Authors:  Anthony J Gill; Angela Chou; Ricardo Vilain; Adele Clarkson; Millie Lui; Richard Jin; Vivienne Tobias; Jaswinder Samra; David Goldstein; Celia Smith; Loretta Sioson; Nicole Parker; Ross C Smith; Mark Sywak; Stan B Sidhu; Jenny Ma Wyatt; Bruce G Robinson; Robert P Eckstein; Diana E Benn; Roderick J Clifton-Bligh
Journal:  Am J Surg Pathol       Date:  2010-05       Impact factor: 6.394

9.  Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients.

Authors:  Anthony J Gill; Ondrej Hes; Thomas Papathomas; Monika Šedivcová; Puay Hoon Tan; Abbas Agaimy; Per Arne Andresen; Andrew Kedziora; Adele Clarkson; Christopher W Toon; Loretta Sioson; Nicole Watson; Angela Chou; Julie Paik; Roderick J Clifton-Bligh; Bruce G Robinson; Diana E Benn; Kirsten Hills; Fiona Maclean; Nicolasine D Niemeijer; Ljiljana Vlatkovic; Arndt Hartmann; Eleonora P M Corssmit; Geert J L H van Leenders; Christopher Przybycin; Jesse K McKenney; Cristina Magi-Galluzzi; Asli Yilmaz; Darryl Yu; Katherine D Nicoll; Jim L Yong; Mathilde Sibony; Evgeny Yakirevich; Stewart Fleming; Chung W Chow; Markku Miettinen; Michal Michal; Kiril Trpkov
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

10.  Succinate dehydrogenase deficiency is rare in pituitary adenomas.

Authors:  Anthony J Gill; Christopher W Toon; Adele Clarkson; Loretta Sioson; Angela Chou; Ingrid Winship; Bruce G Robinson; Diana E Benn; Roderick J Clifton-Bligh; Trisha Dwight
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

View more
  1 in total

Review 1.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.